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dard OS extrapolation methods which fit ‘traditional’ parametric survival
distributions to patient-level data, two different methods were explored in the
modelling of OS beyond the trial duration (55 months) for the novel immunother-
apy ipilimumab. In the first approach, the hazard rate from the Kaplan-Meier (KM)
curve between 24 and 36 months (before reaching a plateau) was used to extend the
curve. In the second approach, different parametric curves were fitted to the period
of 18 months onwards. Akaike’s Information Criterion (AIC) was used to determine
the best fit curve. RESULTS: When compared to standard OS extrapolation meth-
ods, both methods exhibited a better visual fit to the data. Both approaches allow
the hazard of the extrapolated tail to be based on a section of the KM curve that is
more appropriate in describing the long-term survival of these patients. The haz-
ard rate approach does not allow for a formal comparison with AIC, but allows
extrapolation in line with the clinical interpretation. The ‘parametric curves’ ap-
proach allows for a statistically better fit with the patient level data using conven-
tional AIC criteria. Both methods are in line with long-term observations of immu-
notherapy.CONCLUSION: For novel cancer therapies whose KM curves are not well
described by standard survival distributions, other methods of extrapolation
should be explored in conjunction with an understanding of the clinical rationale.
In this case study, two alternatives are presented that describe the OS of immuno-
therapy patients in a more suitable way.
MO3
A METHODOLOGICAL FRAMEWORK FOR DEVELOPING MODELS OF WHOLE
DISEASE AREAS TO INFORM RESOURCE ALLOCATION DECISIONS
Tappenden P, Brennan A, Chilcott J, Squires H
University of Sheffield, Sheffield, South Yorkshire, UK
OBJECTIVES: Conventional economic evaluation involves piecewise comparisons
of competing interventions at a single point in a broader care pathway.METHODS:
This approach is subject to several problems: a) there remains an ongoing debate
surrounding the appropriateness of threshold-based decision rules and whether
their repeated use will maximise health; b) restricting the model scope to a single
decision point means that other adoption decisions elsewhere in the disease path-
way may be treated as independent of the problem under consideration; and c) the
absence of model development guidance leads to inconsistencies between analy-
ses addressing similar decision problems. In light of these problems, this study
puts forward the notion of “Whole Disease Modelling.” This involves simulating
whole disease and treatment pathways within a single model, from preclinical
disease through to diagnosis and referral, adjuvant treatment, follow-up, potential
recurrence, palliative treatment, end-of-life care and eventual death. A method-
ological framework has been developed based on three key principles: 1) the model
boundary and breadth should capture all relevant aspects of the disease and its
treatment; 2) the model should be developed such that the decision node is con-
ceptually transferable across the pathway; and 3) the costs and consequences of
service elements should be structurally related. RESULTS: Case study applications
in colorectal cancer services suggest that Whole Disease Modelling is feasible and
may provide a consistent platform for economic analysis at virtually any point in a
disease pathway using multiple economic decision rules. CONCLUSIONS: The
value of the approach may be realised when: multiple decision problems require
formal economic analysis at a single timepoint; services are subject to rapid inno-
vation and the model can be re-used; a substantial proportion of currently provided
service elements have not previously been subjected to economic analysis, and;
standard cost-utility decision rules fail to reflect the complexity of the decision-
makers’ objectives.
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OUTCOMES BEYOND HEALTH
Joore MA1, Dellaert B2, Spijkers L1, Severens JL3, Krabbe P4, Dirksen C5
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OBJECTIVES: The aim of this study was to investigate whether broadening the
evaluative space in an economic evaluation would lead to other outcomes, and
hence policy recommendations. METHODS: Two discrete choice experiments
(DCE) were conducted in a population of patients who had been treated for varicose
vein disease (N390) either by foam sclerotherapy or surgical stripping. In the
Health DCE the treatments were described in terms of health outcomes attributes
only (based on the EQ5D dimensions). In the Extended DCE the treatments were
described in terms of the same health outcomes attributes and other aspects (Wait-
ing time, Probability of retreatment and Nature of treatment). The differences in
the levels were collected in a clinical trial and entered into the preference models
to calculate the differnce in utility between those treatments. The 	U in both
models was standardised on a [-1,1] scale. The incremental costs of foamsclero-
therapy versus surgical stripping, as observed in the clinical trial, amounted to
-€1123. RESULTS: All attributes were statistically significant, except for Waiting
time and Probability of retreatment. The relative importances and the ranks of the
health attributes differed between the models. The patients preferred surgical
treatment if only health outcomes were considered, while the patients preferred
dermatological treatment if also aspects beyond health outcomes were considered
in the choice: 	Uhealth-0.0109; 	Uextended0.3971. When incremental utility
was based on health outcomes only alone, the incremental cost-utility ratio was
€103,027. When incremental utility was based broader outcomes, the incremental
utility ratio indicated dominance. CONCLUSIONS: The results suggest that recom-
mendation for policy would changed if not only health outcomes but also broader
outcomes are considered. The results confirm that a restriction to health outcomes
in the (economic) evaluation of health care leads to the maximization of health, but
not necessarily to the maximization of benefit in a broader sense.
PODIUM SESSION III:
FLOATING THRESHOLDS AND BY PASSES: RISK SHARING AND PATIENT
ACCESS
RS1
LITERATURE REVIEW ON PATIENT ACCESS SCHEMES, FLEXIBLE PRICING
SCHEMES AND RISK SHARING AGREEMENTS FOR MEDICINES
Puig-Peiró R, Mestre-Ferrandiz J, Sussex J, Towse A
Office of Health Economics, London, UK
OBJECTIVES: To identify existing knowledge about the costs and benefits, assessed
either quantitatively or qualitatively, of performance based reimbursement, risk
sharing schemes, patient access schemes, and flexible pricing schemes for
pharmaceuticals. METHODS: A systematic literature review was conducted using
PubMed for the period January 2008 - April 2011. The terms “risk sharing”, “flexible
pricing”, “patient access schemes”, and “performance-based reimbursement” were
searched in titles and abstracts.RESULTS:The search provided 62 records and after
screening the number was reduced to 31. After full assessments of these studies, a
total of 24 formed the basis of the review. More than 40 per cent of the publications
referred to the Multiple Sclerosis Risk Sharing Scheme implemented in the UK
since 2002. The review did not identify any cost benefit analysis evaluating the
overall economic impact of schemes in monetary terms. All studies discussed costs
and benefits qualitatively and in some cases, when known, some costs were re-
ported. Schemes’ key stakeholders – health service employees, companies, regu-
lators –bear different costs and benefits and conflicting incentives may arise. Costs
and benefits widely vary depending on the characteristics of the scheme.
CONCLUSIONS: There is lack of consensus on the welfare consequences of the
schemes and their social desirability. Identified benefits are countered by signifi-
cant costs and the overall balance remains unclear. Further research is necessary:
a) to assess in a transparent way to what extent the transactional costs and admin-
istrative burden are shared between payers and pharmaceutical companies, as
they constitute an important barrier for the implementation of the schemes, and b)
to aid design of a successful Value Based Pricing system for new medicines in the
UK, given the similar principles that underpin outcome-based schemes where
prices are set to match “real world” NHS value in practice.
RS2
COST-EFFECTIVENESS OF END-OF-LIFE, LIFE-EXTENDING INTERVENTIONS:
NICE’S COST-EFFECTIVENESS THRESHOLD EXPLORED
Hamerslag L, Haynes S, Kusel J, Costello S
Costello Medical Consulting Ltd, Cambridge, UK
OBJECTIVES: It is widely recognised that the National Institute for Health and
Clinical Excellence (NICE) in the UK employs cost-effectiveness thresholds in
health technology appraisal decision-making. This incremental cost-effectiveness
ratio (ICER) threshold has been topic of much debate and is estimated to lie around
£30,000 per quality-adjusted life-year (QALY) gained. In December 2008, NICE ap-
proved supplementary advice to reconsider this threshold for life-extending, end-
of-life interventions. This policy applies to treatments indicated for small patient
populations with life expectancies of usually under 24 months, that typically pro-
long survival by at least 3 months. The aim of this study was to explore NICE’s
increased ICER threshold when end-of-life conditions are taken into account.
METHODS: All NICE technology appraisals issued between December 2008 and
June 2011 were reviewed. The appraisals in which end-of-life considerations ap-
plied were identified and ICERs from these appraisals were extracted. RESULTS: In
total, 53 single technology appraisals were published in the timeframe considered;
of these, only 13 fulfilled the end-of-life criteria, all concerning treatments for
cancer. The final ICERs of these 13 interventions ranged from £31,800 to £68,000,
although 10 out of 13 manufacturers employed patient access schemes to lower
these values. Both the highest ICER that was approved and the lowest ICER that was
not approved were £49,300 per QALY gained. Interestingly, both of these appraisals
concerned interventions for the treatment of advanced renal cell carcinoma, im-
plying that other factors must have been taken into account by NICE to reach this
judgement. CONCLUSIONS: Cost-effectiveness seems to be the most important
criterion for NICE in their health technology appraisals. For end-of-life, life-extend-
ing treatments, the cost-effectiveness threshold appears to lie around £50,000 per
QALY. However, review of individual appraisals shows that other factors such as
uncertainty in the estimates and unmet need are also taken into account in NICE’s
decision-making.
RS3
EVIDENCE, PROCESS OR CONTEXT? EXAMINING THE FACTORS THAT DRIVE
COVERAGE DECISIONS OF PHARMACEUTICALS BY HEALTH TECHNOLOGY
ASSESSMENT BODIES IN EUROPE
Cerri K, Fernández JL, Knapp M
London School of Economics and Political Science, London , UK
OBJECTIVES: In Europe, Health Technology Assessment (HTA) bodies produce cov-
erage decisions that guide public funding of pharmaceuticals. This analysis exam-
ines and weights those factors that drive HTA coverage decisions, focusing on the
National Institute for Health and Clinical Excellence (NICE) in England and Wales,
the Scottish Medicines Consortium (SMC), the Dutch College voor Zorgverzekerin-
gen (CVZ), and the French Haute Autorité de Sante (HAS). METHODS: A dataset of
approximately 1000 HTA coverage decisions by NICE, SMC, CVZ and HAS from the
period 2004-2009 was created, containing more than 30 clinical, economic, process
and socio-economic factors extracted from published HTA reports. A three-cate-
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gory outcome variable was used, defined as the decision to ‘recommend’, ‘restrict’
or ‘not recommend’ a technology. Multivariate analyses were conducted to assess
the relative contribution of the explanatory variables on coverage decisions both
within and between HTA bodies. RESULTS: Different combinations of clinical/eco-
nomic evidence, process and socio-economic factors drive HTA coverage decisions
by NICE, SMC, CVZ and HAS. In addition, the same factor may behave differently
according to the nature of the coverage decision. The analysis further suggests
there is a significant difference between HTA bodies in the probability of reaching
a ‘restrict’ or ‘not recommend’ decision outcome relative to a ‘recommend’ out-
come, adjusted for evidence, process and context factors. CONCLUSIONS: This
analysis contributes to the understanding of factors driving HTA coverage deci-
sions by examining multiple European HTA bodies, enhancing the comprehensive-
ness of the factors examined through descriptive and multivariate analyses and by
identifying and weighting the key drivers of the coverage decisions made by the
four HTA bodies between 2004 and 2009. This research further provides relevant
insights to variation among HTA bodies in the determination of patient access to
pharmaceuticals, and implications for collaboration between European HTA bod-
ies.
RS4
THE INTERIM CANCER DRUGS FUND - HOW TO NOT SPEND £50 MILLION
Timm B, Brooks-Rooney C, Hamerslag L, Costello S
Costello Medical Consulting, Cambridge, UK
OBJECTIVES: The Cancer Drugs Fund (CDF) was established in April 2011 by the UK
government, with a pledge of £200 million additional funding for each of the next 3
years to increase patient access to high cost oncology drugs in England. As an
interim measure, £50 million was distributed between the 10 strategic health au-
thorities (SHAs) in England to cover the 6 months from October 2010 to March 2011.
This research aims to identify how the interim CDF (ICDF) was spent, and to discuss
how this could impact utilization of the CDF. METHODS: Data regarding the total
funding allocated to each SHA from the ICDF and how much of this money had
been spent by March 31, 2011 were obtained from SHA websites. Missing data were
accessed through freedom of information requests. RESULTS: Overall, there were
over 2700 applications to the fund, with an average approval rate of 91%. Over the
6 month period covered by the ICDF, approximately £21 million was spent across
the 10 SHAs in England; this constituted 42% of the £50 million allocated. There was
significant variation in the amount spent by each SHA; the highest under-spend
was in the South West, where 75% of funds remained unallocated. Several SHAs
reported the forecasted costs for continuing treatment beyond March 2011; these
costs were incurred in the 2011/12 financial year and therefore were not covered by
the ICDF. Remaining budget is expected to be reclaimed by the Department of
Health. CONCLUSIONS: It is clear that there was a significant under-spend of the
ICDF by all SHAs. It is concerning that many funding applications were rejected,
despite the fact that almost half of the funds remained unallocated. Steps need to
be taken to ensure more effective use of the CDF and to minimise the risk of
regional variations in drug access.
POSTER SESSION I
SELECTED HEALTH CARE TREATMENT STUDIES
Medical Device/Diagnostics – Clinical Outcomes Studies
PMD1
ND-YAG LASER INCIDENCE RATE COMPARISON OF THREE MONOFOCAL
INTRAOCULAR LENSES (IOL) 36 MONTHS AFTER CATARACT SURGERY IN
FRANCE
Lafuma A1, Coulomb S2, Robert J2, Berdeaux G3
1CEMKA-EVAL, Bourg la Reine, France, 2Cemka Eval, Bourg la Reine, France, 3Alcon France,
Rueil-Malmaison, France
OBJECTIVES: The aim of this study was to compare the 36-month Nd-Yag laser (a
treatment of posterior capsular opacification, the most frequent complication of
cataract surgery) incidence rate of three monofocal IOLs: Acrysof SN60WF (Alcon),
Akreos AO-MI-60 (Baush&Lomb) and Hoya YA-60BB (Hoya). METHODS: This is a
retrospective study conducted at 3 French sites. Each centre implanted at least two
of the above IOLs. Patients had to have uncomplicated cataract surgery with at least
2 years of follow-up. Patients implanted with one of the above IOLs were picked up
at random from the surgery theatre registry. Medical data were retrieved from
patient charts. 36-months post surgical data were obtained from the surgeon’s
medical files and from other ophthalmologists, if involved in post-surgical care.
Time to Nd:Yag laser analysis was carried out using Kaplan-Meier survival curves.
Confounding variable imbalances were adjusted with a stepwise Cox model. The
statistical unit is the eye. RESULTS: 126 eyes were implanted with Acrysof, 89 with
Akreos and 85 with Hoya. Patients with Acrysof were younger (72.1, 76.4 and 75.2
years; P0.0007). The sex ratio was 4 males: 6 females. Patient follow-up was longer
in the Hoya eyes (27.8, 20.3 and 32.1 months; P0.002). Eyes implanted with Acrysof
had 1.68 times less Nd-Yag laser than Hoya (P0.06) and 3.43 times less than
Akreos (P0.0001). The results remained unchanged when the analysis was re-
stricted to the events occurring during the first 36 months (HR2.20; P0.009;
HR3.67; P0.0001, respectively). Adjusting for confounding variable unbalances
did not change the results. CONCLUSIONS: This analysis conducted at 36 months
suggests that following usual surgical practice, Acrysof eyes had significantly less
Nd-Yag laser capsulotomy than those implanted with Hoya and Akreos. Conse-
quently, Acrysof eyes were less exposed to Nd-YAG laser complications and expe-
rienced lower post-surgical treatment costs.
PMD2
CLINICAL DECISION RULES FOR ADULTS WITH MINOR HEAD INJURY: A
SYSTEMATIC REVIEW
Harnan SE, Pickering A, Pandor A, Goodacre SW
The University of Sheffield, Sheffield, South Yorkshire, UK
OBJECTIVES:A small number of cases of minor head injury deteriorate, resulting
in serious injury or death. Computed Tomography (CT) identify intracranial
injuries, but because it carries a cost and its own health risk, it should be limited
to those most likely to have an injury. Clinical decision rules aim to identify
these patients. There are many such rules, but it is unclear how their diagnostic
accuracy compare. This study aimed to systematically identify clinical decision
rules for adults with minor head injury and compare the estimated diagnostic
accuracy. METHODS: Several key electronic bibliographic databases (biomedical,
scientific and grey literature), were searched from inception to March 2010. Re-
trieved citations were considered for inclusion by at least two independent review-
ers. Cohort studies that described a clinical decision rule to identify adults with
minor head injury (GCS 13-15) at risk of intracranial injury or injury requiring
neurosurgical intervention were included in the review. Data was extracted by
one reviewer and checked by a second. Studies were quality assessed using the
QuADAS tool. RESULTS: Twenty-two relevant studies were identified. No study
satisfied all quality assessment items. Heterogeneity amongst patient selection
criteria, outcome definitions, and reference standards was identified. The Cana-
dian CT Head Rule (CCHR) high-risk criteria had sensitivity of 99-100% with speci-
ficity of 48-77% for injury requiring neurosurgical intervention. Other rules, such as
New Orleans criteria, NEXUS II, NCWFNS and SIGN produce similar sensitivities but
with lower and more variable specificity values. CONCLUSIONS: The most widely
researched decision rule is the CCHR, which has consistently shown high sensitivity
for identifying injury requiring neurosurgical intervention, with an acceptable speci-
ficity to allow considered use of cranial CT. No other decision rule has been validated
as widely, or demonstrated similarly acceptable results. However, its exclusion criteria
mean it may make it difficult to apply universally.
PMD3
BIOCHEMICAL MARKERS FOR THE IDENTIFICATION OF INTRACRANIAL INJURY
FOLLOWING MINOR HEAD INJURY: A SYSTEMATIC REVIEW AND
META-ANALYSIS
Pickering A, Fitzgerald P, Harnan SE, Pandor A, Goodacre SW
The University of Sheffield, Sheffield, South Yorkshire, UK
OBJECTIVES: Minor head injury (MHI) can lead to deterioration, severe injury and
death in a small number of cases. Using Computed Tomography (CT) scans on all
those with MHI would result in large numbers receiving an unnecessary dose of
radiation. Biochemical markers may be useful in reducing the number of scans.
This study aimed to systematically identify and synthesize data estimating the
diagnostic accuracy of biochemical markers for intracranial injury on CT in pa-
tients with MHI. METHODS: Key databases including MEDLINE, EMBASE & CINAHL
were searched for potentially relevant literature. Studies reporting a cohort of more
than 20 patients, with more than 50% having suffered a MHI (GCS 13-15), and which
tested the diagnostic accuracy of a biochemical marker for intracranial or neuro-
surgical injury were included. Quality was assessed using the QUality Assessment
of Diagnostic Accuracy Studies (QUADAS) checklist. Meta-analysis was used to
estimate pooled sensitivity, specificity and likelihood ratios. RESULTS: Of the 12
included papers, nine provided diagnostic data on protein S100B only, one for
Neuron-Specific Enolase (NSE) only, one for other markers and one study for both
S100B and NSE levels. Data was only extracted and synthesized from S100B studies.
Bayesian meta-analysis of these pooled data for 2442 adult subjects gave sensitivity
of 96.8% (95% High Density Region (HDR), 93.8 to 98.6%) and specificity of 42.5% (95%
HDR, 31.0 to 54.2%) with a negative likelihood ratio of 0.076 (95% HDR, 0.031 to
0.156).CONCLUSIONS: Evidence to support the addition of protein S100B as a triage
tool for CT in MHI patients within three hours of injury is promising. Whilst the
quality of studies is good, results are heterogeneous. S100B has the potential to be
used in conjunction with a clinical decision rule. The marker therefore needs fur-
ther testing as a component within such a diagnostic pathway.
PMD4
EXPERT ELICITATION TO POPULATE EARLY HEALTH ECONOMIC MODELS OF
MEDICAL DIAGNOSTIC DEVICES IN DEVELOPMENT
Haakma W1, Bojke L2, Steuten L1, Ijzerman M1
1University of Twente, Enschede, The Netherlands, 2University of York, York, Heslington, UK
OBJECTIVES:During the development of new diagnostic and therapeutic devices, it
is desirable to indicate their cost-effectiveness and to establish their potential
clinical value to guide further research. In these early stages of development, how-
ever, there are usually limited or no clinical data available. In this study, expert
elicitation was used to estimate uncertain priors of the diagnostic performance of
a new imaging technology, i.e. Photo Acoustic Mammography (PAM). We compared
PAM to Magnetic Resonance Imaging (MRI), in the detection of breast cancer.
METHODS: Expert elicitation was used as a method to formulate the knowledge
and beliefs of experts about the future performance of PAM and to quantify this
information into probability distributions. 18 radiologists estimated the true posi-
tive rate and true negative rate based on existing MRI data and specified the mode,
the lower, and the upper boundaries (95% credible interval). An overall probability
density function (PDF) was determined using the linear opinion pooling method in
which weighting is applied to reflect the performance of individual experts.
RESULTS: The overall PDF indicated a sensitivity ranging from 58.9% to 85.1%, with
a mode of 73.3%. The specificity ranges from 52.2% to 77.6%, with a mode of 66.5%.
Experts expressed difficulties making the estimations, as there is not sufficient
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